US Senate Democrats will decide fate of FDA nominee next Congress
Dr. Heidi Overton speaks at her U.S. Senate confirmation hearing for Food and Drug Administration commissioner on Sept. 24, 2026. (Photo by Tasos Katopodis/Getty Images)
WASHINGTON — The U.S. Senate will not confirm anyone to lead the Food and Drug Administration until after Democrats take control of that chamber next year.
Louisiana Republican Sen. Bill Cassidy announced Tuesday night that as chairman of the panel that oversees FDA nominees, he didn’t intend to rush anyone through during the lame-duck session, which will last through mid-December.
His comments came shortly after the Trump administration withdrew Dr. Heidi Overton, who was supposed to receive a vote in the Health, Education, Labor and Pensions Committee on Wednesday. She testified before the panel in September as part of the confirmation process.
“Tonight, the White House abandoned a viable confirmation path for Dr. Overton,” Cassidy wrote in a social media post. “The (White House) said that this was because she did not have the votes to pass. This was odd as I was having productive conversations with members. I believe she would have had the votes to pass out of committee and pass the full Senate.
“My conversations with her convinced me she would follow the science and push back against decisions that put Americans’ health at risk. The last issue was that pro-life Senators sought final assurances from the Administration regarding the Administration’s commitment to life issues. The Administration withdrew Dr. Overton rather than make such commitments. Unfortunately, with the limited time left, confirming a permanent FDA Commissioner will fall to Senate Democrats.”
Democrats flipped nine Senate seats in this month’s midterm elections and will hold a 56-44 majority starting in January.
The White House did not immediately respond to a request for comment.
Progress with anti-abortion Republican
Susan B. Anthony Pro-Life America had encouraged the committee to delay a confirmation vote for Overton, with Senior Vice President of Legal Strategy Erik Baptist writing in a statement released Nov. 11 that “senators must secure commitments from the administration that it will immediately restore the in-person dispensing requirement for mifepristone and address the serious flaws with the FDA’s mifepristone safety study.”
Missouri Republican Sen. Josh Halwy said Tuesday during a brief hallway interview before the White House withdrew Overton’s nomination that he was encouraged by her responses to questions he sent her after the hearing.
“I sent her a couple of pages of new questions a few weeks ago, and I just got them back. You know, they're actually pretty good,” he said. “She commits to finishing the FDA's mifepristone study by March of 2027. She commits to using all the most recent data. She commits to using private commercial data, including insurer data, where necessary to provide a complete picture, which is something I've been pushing for. So, it's quite a series of commitments. Every commitment I asked her to give, she made.”
Hawley added that he didn’t know if the committee would still vote on whether to advance Overton’s nomination several hours before that part of the markup was cancelled.
“Your guess is as good as mine,” he said. “I know that there's building frustration on the committee about the inability of the committee to figure out what it's doing. My colleagues are getting a little irritated.”
Hawley was one of several senators who pressed Overton on her beliefs about medication abortion during the confirmation hearing.
Medication abortion a persistent concern
The two-pharmaceutical regimen consisting of mifepristone and misoprostol is FDA-approved for up to 10 weeks gestation. It can be prescribed via telehealth and shipped through the mail, a change the FDA made during the Biden administration that many Republicans want to see reversed.
The FDA has been conducting its own safety review for much of the last two years. Former Commissioner Marty Makary was forced out of the job in May amid frustration from anti-abortion groups that the agency didn’t plan to release its report ahead of the midterm elections.
Marjorie Dannenfelser, president of Susan B. Anthony Pro-Life America, and Lila Rose, founder of Live Action, both released statements in December pressing for the FDA to restrict access to mifepristone.
“The FDA needs a new commissioner who will immediately reinstate in-person dispensing as it existed under President Trump’s first term and immediately conduct a comprehensive study,” Dannenfelser wrote in a statement at the time. “Commissioner Makary is severely undermining President Trump and Vice President Vance’s pro-life credentials and their position that states should have the right to enact and enforce pro-life protections. Makary must go.”
All States Newsroom content is free to republish. Read our republishing policy for more information.